Most Read This Week
- Outcomes of Tucatinib Combination Treatment After Trastuzumab Deruxtecan Therapy in Patients With ERBB2-Positive Metastatic Breast Cancer
- Outcomes of Fulvestrant, Palbociclib, and Avelumab Treatment After Progression on CDK4/6i and Aromatase Inhibitor Therapy for HR+/HER2− Metastatic Breast Cancer
- Survival Outcomes Among Patients With Untreated Metastatic Breast Cancer
- Impact of Initial Tumor Response on Survival Outcomes in Patients With HER2+ Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab
- Patient Advocate–Led Survey Results Regarding MBC Treatment Side Effects and Impact on Quality of Life
Recently Updated
- Outcomes of Tucatinib Combination Treatment After Trastuzumab Deruxtecan Therapy in Patients With ERBB2-Positive Metastatic Breast Cancer
- Survival Outcomes Among Patients With Untreated Metastatic Breast Cancer
- Development and Methodological Validation of a Modified Staging System for De Novo Metastatic Breast Cancer
- Survival Analysis in Patients With Brain Metastases at Initial Breast Cancer Diagnosis Over the Last Decade
- Outcomes of Fulvestrant, Palbociclib, and Avelumab Treatment After Progression on CDK4/6i and Aromatase Inhibitor Therapy for HR+/HER2− Metastatic Breast Cancer